Russian Heart Failure Journal 2009year Brain natriuretic hormone and left ventricular dysfunction


To access this material please log in or register

Register Authorize
2009/

Brain natriuretic hormone and left ventricular dysfunction

Ageev F.T., Ovchinnikov A.G.

Keywords:

DOI:

At present time natriuretic hormones are commonly used for diagnostics of LV dysfunction. The heart function can be judged by the levels of both atrial and natriuretic hormones. However brain natriuretic hormone and the N-terminal fragment of its precursor closer correlate with parameters of systolic and diastolic function and LV myocardial mass than the atrial hormone. Review considers the use of brain natriuretic hormone in diagnostics of LV dysfunction during monitoring of treatment and evaluation of prognosis.
  1. Espiner EA, Richards AM, Yandle TG, Nicholls MG. Natriuretic hormones. Endocrinol Metab Clin North Am. 1995; 24 (3):481‑509.
  2. Wilkins M, Redondo J, Brown L. The natriuretic peptide-family. Lancet. 1997; 349 (9061):1307–1310.
  3. McDonagh T, Morrison C, Lawrence A et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997; 350 (9081):829‑833.
  4. Francis G, Benedict C, Johnstone D et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990; 82 (5):1724–1729.
  5. Francis G. Vasoactive hormone systems. In Poole-Wilson et al. (eds): Heart failure. Oxford, Churchill Livingstone, 1997:215‑234.
  6. Hunt PJ, Richards AM, Espiner EA et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994; 78 (6):1428–1435.
  7. Thibault G, Amiri F, Garcia R. Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol. 1999; (61):193‑217.
  8. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87 (4):1402–1412.
  9. Rodeheffer R, Tanaka I, Imada T et al. Atrial pressure and secretion of atrial natriuretic factor into the human central circulation. J Am Coll Cardiol. 1986; 8 (1):18–26.
  10. Maack T, Nikonova L, Friedman O et al. Functional properties and dynamics of natriuretic peptide receptors. Proc Soc Exp Biol Med. 1996; 213 (2):109‑116.
  11. Levin RE, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339 (5):321‑328.
  12. Espiner E, Richards A, Nicholls M. Physiology of natriuretic peptides. In: Levin E, Nadler J. (eds). Endocrinology of cardiovascular function. Boston, Kluwer Academic, 1998:121‑135.
  13. Dunn B, Ichikawa I, Pfeffer J et al. Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res. 1986; 59 (3):237‑246.
  14. Marin-Grez M, Fleming J, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature. 1986; 324 (6096):473‑476.
  15. Hunt J, Espiner E, Nicholls M et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab. 1996; 81 (11):3871–3876.
  16. Maack T. Role of atrial natriuretic factor in volume control. Kidney Int. 1996; 49 (6):1732–1737.
  17. Rademaker M, Charles C, Kosoglou T et al. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol. 1997; 273 (5 Pt 2):H2372-2379.
  18. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002; 40 (5):976‑982.
  19. Yamamoto K, Burnett JC Jr, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996; 28 (6):988‑994.
  20. Iwanaga Y, Nishi I, Furuiichi S et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006; 47 (4):742‑748.
  21. Hama N, Itoh H, Shirakami G et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995; 92 (6):1558–1564.
  22. Sumida H, Yasue H, Yoshimura M et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol. 1995; 25 (5):1105–1110.
  23. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol. 2004; 43 (3):416‑422.
  24. Mariano-Goulart D, Eberle M, Boudousq V et al. Major increase in brain natriuretic peptide indicates right ventricular systolic dysfunction in patients with heart failure. Eur J Heart Fail. 2003; 5 (4):481‑488.
  25. Hunt PJ, Yandle TG, Nicholls MG et al. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun. 1995; 214 (3):1175–1183.
  26. Lainchbury JG, Campbell E, Frampton CM et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003; 42 (4):728‑735.
  27. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993; 87 (2):464‑469.
  28. Watanabe S, Shite J, Takaoka H et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J. 2006; 27 (7):832‑838.
  29. Nishikimi T, Yoshihara F, Morimoto A et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension. 1996; 28 (1):22–30.
  30. Tsutamoto T, Wada A, Sakai H et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006; 47 (3):582‑586.
  31. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109 (5):594‑600.
  32. McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003; 41 (3):571‑579.
  33. Lukowicz TV, Fischer M, Hense HW et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail. 2005; 7 (4):525‑531.
  34. Knudsen CW, Omland T, Clopton P et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol. 2005; 46 (5):838‑844.
  35. Costello-Boerrigter LC, Boerrigter G, Redfield MM et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006; 47 (2):345‑353.
  36. Tsuyuki R, Yusuf S, Rouleau J et al. Combination neurohormonal blockade with ACE inhibitors angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997; 13 (12):1166–1174.
  37. Ala-Kopsala M, Magga J, Peuhkurinen K et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A0 and B-type natriuretic peptides. Clin Chem. 2004; 50 (9):1576–1588.
  38. Nishikumi T, Matsuoka H. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. Circulation. 2004; 109 (25):e325-326.
  39. Mehra M, Uber A, Walther D et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation. 2006; 114 (1 Suppl):I21-26.
  40. Joung B, Ha J, Ko Y et al. Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function? Am Heart J. 2005; 150 (6):1213–1219.
  41. Kazanegra R, Cheng V, Garcia A et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001; 7 (1):21–29.
  42. O’Neill JO, Bott-Silverman CE, McRae AT 3rd et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J. 2005; 149 (2):363‑369.
  43. Rodeheffer R. Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol. 2004; 44 (4):740‑749.
  44. Nakamura M, Endo H, Nasu M et al. Value of plasma B-type natriuretic peptide measurement for heart disease screening in Japanese population. Heart. 2002; 87 (2):131‑135.
  45. Niinuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in multiphasic health screening program. Cardiology. 1998; 90 (2):89–94.
  46. Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. J Am Coll Cardiol. 2002; 40 (5):976‑982.
  47. Vasan RS, Benjamin EJ, Larson MG et al. Plasma natriuretic peptides for community sreening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002; 288 (10):1252–1259.
  48. Gerber IL, Stewart RA, French JK et al. Associations between plasma plasma natriuretic peptide levels, symptoms and left ventricular function in patients with chronic aortic regurgitation. Am J Cardiol. 2003; 92 (6):755‑758.
  49. Gerber I, Stewart R, Legget M et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003; 107 (14):1884–1890.
  50. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation. 2002; 105 (5):595‑601.
  51. Maisel AS, Koon J, Krishnaswamy P et al. Utility of B-natriuretic pepetide as a rapid point-of-care test for screening patients undergoing ecgocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141 (3):367‑374.
  52. Krishnaswamy P, Lubien E, Clopton P et al. Utility of B-natriuretic pepetide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med. 2001; 111 (4):274‑279.
  53. Овчинников А, Свирида О, Агеев Ф, и др. Влияние диастолической дисфункции на содержание маркеров баланса коллагена и NT-proBNP у больных с сердечной недостаточностью и относительно сохранённой систолической функцией левого желудочка. Сборник тезисов ежегодной конференции и II-ого Конгресса Общества специалистов по сердечной недостаточности «Сердечная недостаточность 2007», Москва, 6–8 декабря 2007 г, стр. 6.
  54. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; 10 (10):933‑989.
  55. Kitzman DW, Little WC, Brubaker PH et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002.; 288 (17):2144–2150.
  56. Bursi F, Weston SA, Redfield MM et al. Systolic and Diastolic Heart Failure in the Community. JAMA. 2006; 296 (18):2209–2216.
  57. Paulus WJ, Tschope C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007; 28 (20):2539–2550.
  58. Tschope C, Kasner M, Westermann D et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005; 26 (21):2277–2284.
  59. Caruana L, Petrie MC, Davie AP, McMurray JJ. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from «diastolic heart failure» or from misdiagnosis? A prospective descriptive study. BMJ. 2000; 321 (7255):215‑218.
  60. Wright SP, Doughty RN, Pearl A et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol. 2003; 42 (10):1793–1800.
  61. Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet. 1994; 343 (8895):440‑444.
  62. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347 (3):161‑167.
  63. Januzzi JL, van Kimmenade R, Lainchbury J et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J. 2006; 27 (3):330‑337.
  64. Lainchbury JG, Campbell E, Frampton CM et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003; 42 (4):728‑735.
  65. Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from Breathing Not Properly (BNP) multinational study. Am Heart J. 2004; 147 (6):1078–1084.
  66. Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003; 41 (11):2010–2017.
  67. Mueller C, Scholer A, Laule-Kilian K et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004; 350 (7):647‑654.
  68. Colluci WS, Elkayam U, Horton DP et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000; 343 (4):246‑253.
  69. Yoshimura M, Yasue H, Morita E et al. Hemodinamic renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 1991; 84 (4):1581–1588.
  70. Lainchbury J, Richards A, Nicholls M et al. The effects of pathophysiological increments in brain natriuretic peptide in left ventricular systolic dysfunction. Hypertension. 1997; 30 (3 Pt 1):398‑404.
  71. Latini R, Masson S, Anand I et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25 (4):292‑299.
  72. Logeart D, Thabut G, Jourdain P et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004; 43 (4):635‑641.
  73. Latini R, Masson S, Wong M et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006; 119 (1):70.e23-30.
  74. Arnand IS, Fisher LD, Chiang Y-T et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFt). Circulation. 2003; 107 (9):1278–1283.
  75. Kirk V, Bay M, Parner J et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail. 2004; 6 (3):335‑341.
  76. Wang TJ, Larson MG, Levy D. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004 12; 350 (7):655‑663.
  77. Hartmann F, Packer M, Coats AJ. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004; 110 (13):1780–1786.
  78. Hunt SA, Abraham WT, Chin MH. ACC / AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005; 46 (6):e1-82.
  79. Blankenberg S, McQueen M, Smieja M et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2006; 114 (3):201‑208.
  80. Morrow D, de Lemos J, Blazing M et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005; 294 (22):2866–2871.
  81. Cheng V, Kazanagra R, Garcia A et al. A rapid bedside test for B-type peptide predict treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol. 2001; 37 (2):386‑391.
  82. Dias P, Rodrigues R, Queiros M et al. Prognosis in patients with heart failure and preserved left ventricular systolic function. Rev Port Cardiol. 2001; 20 (12):1223–1232.
  83. Bettencourt P, Ferreira S, Azevedo A et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am J Med. 2002; 113 (3):215‑219.
  84. Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol. 2002; 39 (10):1623–1629.
  85. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355 (9210):1126–1130.
  86. Jourdain P, Funck F, Gueffet P et al. Benefits of BNP plasma levels for optimizing therapy: the systolic heart failure treatment supported by BNP multicenter randomized trial (STABS-BNP). J Am Coll Cardiol. 2007; 49 (16):1733–1739.
  87. Bergstrom A, Andersson B, Edner M et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiography study (SWEDIC). Eur J Heart Fail. 2004; 6 (4):453‑461.
  88. Mottram M, Haluska B, Leano R et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004; 110 (5):558‑565.
  89. Fung J, Yu C, Yip G et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003; 92 (4):406‑410.
  90. Rousseau M, Gurne O, van Eyll C et al. Effects of benazeprilat on left ventricular systolic and diastolic function and neurohumoral status in patients with ischemic heart disease. Circulation. 1990; 81 (2 Suppl):III123-129.
  91. Brunner-La Rocca H, Buser T, Schindler R et al. Management of elderly patients with congestive heart failure – design of Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J. 2006; 151 (5):949‑955.
  92. Lainchbury JG, Troughton RW, Frampton CM et al. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the «BATTLESCARRED» trial. Eur J Heart Fail. 2006; 8 (5):532‑538.
  93. Wu AH, Smith A, Wieczorek S et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003; 92 (5):628‑631.
  94. Braunschweig F, Fahleitner-Pammer A, Mangiavacci M et al. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail. 2006; 8 (8):797‑803.
  95. Bruins S, Fokkema M, Romer J et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem. 2004; 50 (11):2052–2058.
  96. Свирида О, Овчинников А, Агеев Ф, и др. Приём блокатора ангиотензиновых рецепторов кандесартана изолированно или в сочетании с антагонистом рецепторов к альдостерону спиронолактоном у больных с сердечной недостаточностью и сохранённой систолической функцией левого желудочка. Сборник тезисов ежегодной конференции, II-ого Конгресса Общества специалистов по сердечной недостаточности «Сердечная недостаточность 2007», Москва, 6–8 декабря 2007 г, стр. 5.
  97. Richards M, Nicholls M, Espiner E et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol. 2006; 47 (1):52–60.
  98. Richards A, Nicholls M, Espiner E et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003; 107 (22):2786–2792.
  99. Richards A, Nicholls M, Yandle T et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998; 97 (19):1921–1929.
  100. de Lemos JA, Morrow DA, Bentley JH. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345 (14):1014–1021.
  101. Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996; 93 (11):1963–1969.
  102. Bibbins-Domingo K, Ansari M, Schiller N et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003; 108 (24):2987–2992.
  103. Hillis GS, Moller JE, Pellikka PA et al. Noninvasive estimation of left ventricular filling pressure by E / e’ is a powerful predictor of survival after acute myocardial infarction. J Am Coll Cardiol. 2004; 43 (3):360‑367.
  104. Moller JE, Hillis GS, Oh JK et al. Wall motion score index and ejection fraction for risk stratification after acute myocardial infarction. Am Heart J. 2006; 151 (2):419‑425.
  105. Yamaguchi H, Yoshida K, Sakata Y. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004; 43 (1):55–60.
  106. Furumoto T, Fujii S, Mikami T et al. Increased plasma concentrations of N-terminal pro-brain natriuretic peptide reflect the presence of mildly reduced left ventricular diastolic function in hypertension. Coron Artery Dis. 2006; 17 (1):45–50.
  107. Luchner A, Burnett JC Jr, Jougasaki M et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000; 18 (8):1121–1128.
  108. Овчинников А, Сербул В, Габрусенко С. и др. Содержание мозгового натрийуретического пептида у пациентов с гипертрофией левого желудочка различной этиологии. Сборник тезисов Ежегодной Всероссийской конференции Общества специалистов по сердечной недостаточности, Москва, 7–9 декабря 2006 г, стр. 54.
  109. Lim T, Ashrafian H, Dwivedi G et al. Increased left atrial volume index is a independent predictor of raised serum natriuretic peptide in patients with suspected heart failure but normal left ventricular ejection fraction: implication for diagnosis of diastolic heart failure. Eur J Heart Fail. 2006; 8 (1):38–45.
  110. Wei T, Zeng C, Chein L et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail. 2005; 7 (1):75–79.
  111. Opie L. Overload hypertrophy and its molecular biology. In: Opie L. Heart physiology: from cell to circulation. 4th ed. Philadelphia, Lippincott Williams & Wilkins, 2004.
  112. Сербул В. Влияние амбулаторной терапии блокаторами ангиотензиновых рецепторов, ингибиторами ангиотензин-превращающего фермента и их комбинацией на клиническое течение, морфофункциональные показатели сердца и маркеры фиброза у больных с артериальной гипертонией и гипертрофией левого желудочка. Автореферат диссертации на соискание ученой степени к.м.н. Москва, 2008 г.; стр. 1–28.
  113. Freitag MH, Larson MG, Levy D et al. Plasma brain natriuretic peptide levels and blood pressure tracking in the Framingham Heart Study. Hypertension. 2003; 41 (4):978‑983.
  114. Maron B, Tholakanahalli V, Zenovich A et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004; 109 (8):984‑989.
  115. Briguori C, Betocchi S, Manganelli F et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J. 2001; 22 (15):1328–1336.
  116. Kim S, Park S, Lim S et al. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction. Clin Cardiol. 2006; 29 (4):155‑160.
  117. Arteaga E, Araujo A, Buck P et al. Plasma amino-terminal pro-B-type natriuretic peptide quantification in hypertrophic cardiomyopathy. Am Heart J. 2005; 150 (6):1228–1232.
  118. Сафрыгина Ю. В., Габрусенко С. А., Овчинников А. Г. и др. Сердечные натрийуретические пептиды у больных с гипертрофической кардиомиопатией. Кардиология. 2007; 47 (5):50–57.
  119. Ogino K, Ogura K, Kinugawa T et al. Neurohumoral profiles in patients with hypertrophic cardiomyopathy: differences to hypertensive left ventricular hypertrophy. Circ J. 2004; 68 (5):444‑450.
  120. Nakamura T, Sakamoto K, Yamano T et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39 (10):1657–1663.
  121. Palladini G, Campana C, Klersy C et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003; 107 (19):2440–2445.
  122. Vanderheyden M, Goethals M, Verstreken S et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol. 2004; 44 (12):2349–2354.
  123. Ikeda T, Matsuda K, Iton H et al. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patientws with aortic stenosis. Am Heart J. 1997; 133 (3):307‑314.
  124. Sutton T, Stewart R, Gerber I et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol. 2003; 41 (12):2280–2207.
  125. Leya F, Arab D, Joyal D et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol. 2005; 45 (11):1900–1902.

To access this material please log in or register

Register Authorize
Ru En